Skip to main content

Combination of Nivolumab and Relatlimab Approved for Unresectable or Metastatic Melanoma

The FDA has approved the combination of nivolumab and relatlimab-rmbw (Opdualag™, Bristol-Myers Squibb) for patients with unresectable or metastatic melanoma. OpdualagTM is a fixed-dose dual immunotherapy combination of nivolumab, a programmed cell death protein 1 (PD-1)–blocking antibody, and relatlimab, a first-in-class human lymphocyte–activation gene 3 (LAG-3)–blocking antibody, and is administered as a single intravenous (IV) infusion. "LAG-3 and PD-1 are distinct inhibitory immune checkpoi...

Continue reading